Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07449091 · ClinicalTrials.gov registry record
Adaptability of an Undetectable = Untransmissible Model for HBV
A clinical trial, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- 55
- Enrollment target
NCT07449091: Recruiting study, sponsored by NYU Langone Health.
NCT07449091 is a clinical trial that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07449091 is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- 55 participants
- Enrollment target
Study Summary
Persons with chronic hepatitis B (HBV) infection and active viremia are infectious and may transmit virus to others through blood/body fluid exposure. Immune tolerant treatment naive persons with hepatitis B infection express anxiety regarding disclosure of their infection status and significant fear of transmission to their partners leading to social isolation and impact on their personal lives. This study will provide data correlating serum and body fluid viral levels in persons with chronic hepatitis B infection not on therapy and those with viral suppression on long-term anti-retroviral therapy (ART) that may support the concept of "Undetectable=Untransmissible" (U=U) in patients with chronic hepatitis B.
Primary Outcome
Assessed among those who have achieved viral supression.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2027-09 |
What NCT07449091 shows while recruiting
NCT07449091 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT07449091 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07449091 about?
NCT07449091 is a clinical study titled "Adaptability of an Undetectable = Untransmissible Model for HBV". Persons with chronic hepatitis B (HBV) infection and active viremia are infectious and may transmit virus to others through blood/body fluid exposure. Immune tolerant treatment naive persons with hepatitis B infection express anxiety regarding disclosure of their infection status and significant fea...
What is the current status of trial NCT07449091?
This trial is currently recruiting. The enrollment target is 55 participants. The study started on 2026-05-01. Estimated completion is 2027-09.
Who is sponsoring clinical trial NCT07449091?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI